These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20040526)

  • 21. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
    Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
    Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval.
    Agard C; Carpentier PH; Mouthon L; Clerson P; Gressin V; Bérezné A; Diot E; Jego P; Lok C; Sparsa A; Chatelus E; Van Kien AK; Quéré I; Sibilia J; Hachulla E
    Scand J Rheumatol; 2014; 43(5):398-402. PubMed ID: 24720440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
    Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
    Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
    Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
    J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
    Denton CP; Hachulla É; Riemekasten G; Schwarting A; Frenoux JM; Frey A; Le Brun FO; Herrick AL;
    Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
    Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
    Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
    Nishibu A; Sakai E; Oyama N; Yamamoto T
    Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
    Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
    N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
    Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
    Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
    Lee EY; Park JK; Lee W; Kim YK; Park CS; Giles JT; Park JW; Shin K; Lee JS; Song YW; Lee EB
    Rheumatology (Oxford); 2014 Apr; 53(4):658-64. PubMed ID: 24352340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
    García de la Peña-Lefebvre P; Rodríguez Rubio S; Valero Expósito M; Carmona L; Gámir Gámir ML; Beltrán Gutiérrez J; Díaz-Miguel C; Orte Martínez J; Zea Mendoza AC
    Rheumatology (Oxford); 2008 Apr; 47(4):464-6. PubMed ID: 18263597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bosentan for digital ulcers in patients with systemic sclerosis.
    Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
    J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Behr J; Brown KK; du Bois RM; Lancaster L; de Andrade JA; Stähler G; Leconte I; Roux S; Raghu G
    Am J Respir Crit Care Med; 2008 Jan; 177(1):75-81. PubMed ID: 17901413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ; Mariz HA; Andrade LE; Kayser C
    Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.